CR20120443A - Derivados de (imidazopirimidina-7-il)-heteroarilamida y su uso como inhibidores de pde10a - Google Patents

Derivados de (imidazopirimidina-7-il)-heteroarilamida y su uso como inhibidores de pde10a

Info

Publication number
CR20120443A
CR20120443A CR20120443A CR20120443A CR20120443A CR 20120443 A CR20120443 A CR 20120443A CR 20120443 A CR20120443 A CR 20120443A CR 20120443 A CR20120443 A CR 20120443A CR 20120443 A CR20120443 A CR 20120443A
Authority
CR
Costa Rica
Prior art keywords
derivatives
imidazopirimidina
heteroarilamida
pde10a inhibitors
pde10a
Prior art date
Application number
CR20120443A
Other languages
English (en)
Inventor
Sanchez Ruben Alvarez
Konrad Bleicher
Alexander Flohr
Luca Gobbi
Zbinden Katrin Groebke
Matthias Koerner
Bernd Kuhn
Jens-Uwe Peters
Markus Rudolph
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20120443A publication Critical patent/CR20120443A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención se refiere a nuevos derivados de imidazopirimidina de la fórmula (I) en la que R1, R2 y R8 tienen los significados definidos en la descripción y en las reivindicaciones, así como a sus sales y ésteres fisiológicamente aceptables. Estos compuestos inhiben la PDE10A y pueden utilizarse como medicamentos.
CR20120443A 2010-03-26 2012-08-24 Derivados de (imidazopirimidina-7-il)-heteroarilamida y su uso como inhibidores de pde10a CR20120443A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10158011 2010-03-26

Publications (1)

Publication Number Publication Date
CR20120443A true CR20120443A (es) 2012-10-11

Family

ID=43989818

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120443A CR20120443A (es) 2010-03-26 2012-08-24 Derivados de (imidazopirimidina-7-il)-heteroarilamida y su uso como inhibidores de pde10a

Country Status (25)

Country Link
US (1) US8410117B2 (es)
EP (1) EP2552918B1 (es)
JP (1) JP5764196B2 (es)
KR (1) KR20130073876A (es)
CN (1) CN102791714B (es)
AR (1) AR080785A1 (es)
AU (1) AU2011231668A1 (es)
BR (1) BR112012024199A2 (es)
CA (1) CA2786213A1 (es)
CL (1) CL2012002497A1 (es)
CR (1) CR20120443A (es)
EC (1) ECSP12012174A (es)
ES (1) ES2478448T3 (es)
HK (1) HK1173440A1 (es)
IL (1) IL220932A0 (es)
MA (1) MA34069B1 (es)
MX (1) MX2012010880A (es)
NZ (1) NZ600927A (es)
PE (1) PE20130382A1 (es)
RU (1) RU2562066C2 (es)
SG (1) SG183824A1 (es)
TW (1) TWI478924B (es)
UA (1) UA108640C2 (es)
WO (1) WO2011117264A1 (es)
ZA (1) ZA201206257B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8772316B2 (en) 2011-02-18 2014-07-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE10A)
AU2012325909B2 (en) 2011-10-20 2016-06-09 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
JP2014530870A (ja) * 2011-10-20 2014-11-20 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ
EP2768833A4 (en) * 2011-10-20 2015-04-15 Sirtris Pharmaceuticals Inc SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS MODULATORS OF SIRTUINS
MX348635B (es) * 2012-08-17 2017-06-22 Hoffmann La Roche Proceso para preparación de derivados de ácido pirazol carboxílico.
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
MX2015005375A (es) * 2012-11-07 2015-07-21 Hoffmann La Roche Compuestos de triazolo.
CN102964308B (zh) * 2012-11-30 2015-03-18 中国药科大学 新型嘧啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
AU2014221799B2 (en) * 2013-02-27 2017-09-28 Mochida Pharmaceutical Co., Ltd. Novel pyrazole derivative
WO2014187762A1 (en) 2013-05-23 2014-11-27 F. Hoffmann-La Roche Ag 2-phenylimidazo[1,2-a]pyrimidines as imaging agents
WO2015006689A1 (en) 2013-07-12 2015-01-15 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression
CA2920068A1 (en) * 2013-09-26 2015-04-02 F. Hoffmann-La Roche Ag Imidazo[1,2-a]pyridin-7-amines as imaging tools
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
PL408251A1 (pl) 2014-05-19 2015-11-23 Celon Pharma Spółka Z Ograniczoną Odpowiedzialnością Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A
WO2016017711A1 (ja) * 2014-07-30 2016-02-04 持田製薬株式会社 ピラゾール誘導体の製造方法
EP3365340B1 (en) 2015-10-19 2022-08-10 Incyte Corporation Heterocyclic compounds as immunomodulators
MD3377488T2 (ro) 2015-11-19 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
SG11201805300QA (en) 2015-12-22 2018-07-30 Incyte Corp Heterocyclic compounds as immunomodulators
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
CA3028685A1 (en) 2016-06-20 2017-12-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180016260A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2941716T3 (es) 2016-08-29 2023-05-25 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
HRP20221216T1 (hr) 2016-12-22 2022-12-23 Incyte Corporation Derivati tetrahidro imidazo[4,5-c]piridina kao induktori internalizacije pd-l1
US20180179201A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2934230T3 (es) 2016-12-22 2023-02-20 Incyte Corp Derivados de benzooxazol como inmunomoduladores
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
TWI674260B (zh) 2017-02-01 2019-10-11 德商菲尼克斯製藥股份有限公司 芳基烴受體(AhR)調節劑化合物
TWI752155B (zh) * 2017-02-01 2022-01-11 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
FI3774791T3 (fi) 2018-03-30 2023-03-21 Incyte Corp Heterosyklisiä yhdisteitä immunomodulaattoreina
CN112752756A (zh) 2018-05-11 2021-05-04 因赛特公司 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物
WO2020094592A1 (en) 2018-11-06 2020-05-14 H. Lundbeck A/S Compounds for treating negative symptoms and cognitive impairments
WO2020094591A1 (en) 2018-11-06 2020-05-14 H. Lundbeck A/S Pde10a inhibitors for treating negative symptoms and cognitive impairments in a patient suffering from schizophrenia
TW202115059A (zh) 2019-08-09 2021-04-16 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之鹽
AU2020357514A1 (en) 2019-09-30 2022-04-07 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
JP2022553323A (ja) * 2019-10-21 2022-12-22 エスケー バイオファーマスティカルズ カンパニー リミテッド 認知障害の予防、軽減又は治療、又は認知機能の改善のためのイミダゾピリミジン又はイミダゾトリアジン化合物の使用
WO2021096849A1 (en) 2019-11-11 2021-05-20 Incyte Corporation Salts and crystalline forms of a pd-1/pd-l1 inhibitor
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
IL302590A (en) 2020-11-06 2023-07-01 Incyte Corp Process for preparing PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
CN115572282A (zh) * 2021-07-05 2023-01-06 华东理工大学 含芳杂环结构的吡唑酰胺类化合物及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES493459A0 (es) 1980-07-17 1981-07-01 Consejo Superior Investigacion Procedimiento para la preparacion de 3(6 5)-formilpira- zol-4-carboxilatos de alquilo
NZ512957A (en) * 1999-11-10 2005-01-28 Ortho Mcneil Pharm Inc Substituted 2-aryl-3-(heteroaryl)-imidazo[1,2-a] pyrimidines and their use in inhibiting in vitro secretion of TNF-alpha and IL-1beta to treat neurodegenerative diseases
AU783521B2 (en) 2000-05-24 2005-11-03 Merck Sharp & Dohme Limited 3-phenyl-imidazo-pyrimidine derivatives as ligands for GABA receptors
US6596731B2 (en) 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
KR20060034303A (ko) * 2003-07-30 2006-04-21 라보라토리오스 에스.에이.엘.브이.에이.티., 에스.에이. 암을 예방하고 치료하기 위한 치환된 이미다조피리미딘
US20070032404A1 (en) 2003-07-31 2007-02-08 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
WO2007034282A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists
BRPI0706560A2 (pt) * 2006-01-17 2011-03-29 Hoffmann La Roche derivados de aril-isoxazol-4-il-imidazo [1,2-a] piridina úteis para o tratamento de doença de alzheimer por intermédio de receptores gaba
US7951824B2 (en) 2006-02-17 2011-05-31 Hoffman-La Roche Inc. 4-aryl-pyridine-2-carboxyamide derivatives
ES2689444T3 (es) * 2006-11-22 2018-11-14 Incyte Holdings Corporation Imidazotriazinas e imidazopirimidinas como inhibidores de la quinasa
EP1964841A1 (en) * 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]azine and their use as pharmaceuticals
DE102007048716A1 (de) * 2007-10-11 2009-04-23 Merck Patent Gmbh Imidazo[1,2-a]pyrimidinderivate
FR2926556B1 (fr) * 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
TWI501965B (zh) * 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物

Also Published As

Publication number Publication date
UA108640C2 (uk) 2015-05-25
ECSP12012174A (es) 2012-10-30
BR112012024199A2 (pt) 2016-07-05
US8410117B2 (en) 2013-04-02
ZA201206257B (en) 2013-05-29
CA2786213A1 (en) 2011-09-29
CL2012002497A1 (es) 2013-03-22
TWI478924B (zh) 2015-04-01
WO2011117264A1 (en) 2011-09-29
RU2012143794A (ru) 2014-05-10
JP5764196B2 (ja) 2015-08-12
SG183824A1 (en) 2012-10-30
MA34069B1 (fr) 2013-03-05
AU2011231668A1 (en) 2012-07-19
EP2552918A1 (en) 2013-02-06
US20110237564A1 (en) 2011-09-29
CN102791714A (zh) 2012-11-21
JP2013523673A (ja) 2013-06-17
TW201136937A (en) 2011-11-01
KR20130073876A (ko) 2013-07-03
RU2562066C2 (ru) 2015-09-10
EP2552918B1 (en) 2014-06-11
HK1173440A1 (en) 2013-05-16
NZ600927A (en) 2013-08-30
ES2478448T3 (es) 2014-07-22
AR080785A1 (es) 2012-05-09
MX2012010880A (es) 2012-10-15
PE20130382A1 (es) 2013-03-30
CN102791714B (zh) 2015-03-25
IL220932A0 (en) 2012-09-24

Similar Documents

Publication Publication Date Title
CR20120443A (es) Derivados de (imidazopirimidina-7-il)-heteroarilamida y su uso como inhibidores de pde10a
CR20130239A (es) Compuestos de triazolopiridina
ECSP13013074A (es) Nuevos derivados de piridina
GT201300266A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
UY33440A (es) ?compuestos pirimidinílicos para uso como inhibidores de atr?.
GT201400196A (es) Compuestos de heterociclilo
CR20150250A (es) Nuevos derivados de piridina
CO6620065A2 (es) Compuestos heteroarilo nitrogenados
CO6541606A2 (es) Espiroindolinona- pirrolidinas
CO6430459A2 (es) Derivados de prolina como inhibidores de catepsina
CR20150175A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
DOP2013000221A (es) INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
CR20150204A (es) Nuevos derivados de piridina
CR20120634A (es) Derivados de heteroaril imidazolona como inhibidores de jak
EA201490599A1 (ru) Соединения триазолопиридина в качестве ингибиторов фосфодиэстеразы pde10a
CR20140481A (es) Compuestos triazolo como inhibidores de pde10
CR20150210A (es) Nuevos derivados de pirazina como agonistas receptores de cb2
CU20110233A7 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas
UY33874A (es) Derivados de ácido 3-heteroaroilamino-propiónico sustituidos y su uso como sustancias farmacéuticas
UY35087A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
UY31000A1 (es) Oxoisoxazoles como inhibidores de lipasas y fosfolipasas
CR20130318A (es) Nuevos compuestos de benzodioxol-piperazina
ECSP15015088A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
CU20100092A7 (es) Inhibidores de beta-lactamasa